Evidence map›Paper›PMID 35246605›Full record

ArticleLeukemia2022

Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era.

Manette A W Dinnessen, Carolien C H M Maas, Sanne H Tonino, Otto Visser, Eduardus F M Posthuma, Nicole M A Blijlevens, Marie José Kersten, Pieternella J Lugtenburg, Avinash G Dinmohamed

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Manette A W DinnessenDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. m.dinnessen@iknl.nl.ORCID http://orcid.org/0000-0001-5863-7897
Carolien C H M MaasDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Sanne H ToninoAmsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands.
Otto VisserDepartment of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Eduardus F M PosthumaDepartment of Internal Medical, Reinier de Graaf Gasthuis, Delft, The Netherlands.
Nicole M A BlijlevensDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Marie José KerstenAmsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands.
Pieternella J LugtenburgDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Avinash G DinmohamedDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-4767-6716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, FollicularAntineoplastic Combined Chemotherapy ProtocolsCause of DeathHumansNetherlandsRituximabRituximab

Identifiers

PMID35246605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.